// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

App it

Faisal Ahmed - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Novel therapies for Bestrophinopathies

Amanda-Jayne Carr - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Antisense oligonucleotide treatment in CEP290‐related leber congenital amaurosis

Bart P Leroy - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Leber congenital amaurosis

N/A

Axon transport as a target for promoting RGC survival and optic nerve regeneration

Richard Eva - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Phakic intraocular lens implantation in Keratoconus

Valerie Saw - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Keratoconus

N/A

Immune mediators of host defence at the Ocular surface and Cornea

Harminder DUA - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Lactoferrin

Sex Differences in Modifiable Risk Factors and Severity of Coronary Artery Disease

Edina Cenko - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Causes of Cardiovascular and Non-cardiovascular Mortality in the Ischemia Trial

Mandeep S Sidhu - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Incorporation of High-Sensitivity Troponin Along With the AHA/ACC Cholesterol Guidelines for Improved Risk Stratification and Targeted PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease

Nicholas A Marston - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Evolocumab

Efficacy of Lowering Low-density Lipoprotein Cholesterol in Elderly Subjects: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Baris Gencer - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Patients With NSTEMI Are at Higher Risk, Have Worse Outcomes, but Less Intense Cardiology Follow-up 1-3 Years Post-discharge: Findings From the TIGRIS Registry

Sibi N Krishnamurthy - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Duration of Dual Antiplatelet Therapy in Coronary Heart Disease: A 60,000-patient Meta-analysis of Randomised Controlled Trials

Anda Bularga - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Coronary Artery Disease

N/A

Clinical Significance of Troponin Elevation in a Contemporary Hospitalized Population: Endotypes, Morbidity and In-hospital Mortality

Michael Briscoe - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Interleukin-1beta Inhibition Attenuates Accelerated Atherosclerosis in Mice With Tet2 Loss of Function in a Sex-dependent Fashion

Amelie Vromman - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Atherosclerotic lesions

Interleukin

The Clonal Hematopoiesis MutationJak2V617FAggravates NETosis and Endothelial Injury in Mouse Arteries With Erosion-like Intimas

Roberto Molinaro - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Vasodilation dysfunction

N/A

Targeting Store Operated Calcium Entry in Vascular Smooth Muscle Cells by a Novel Small-molecule Inhibitor

Heba Shawer - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Angiology

Calcified vascular disease

Becaplermin

Oxidation of PKA-RIα Protects Against Ischemia-reperfusion Injury by Inhibiting Lysosomal-triggered Calcium Release

Jillian N Simon - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Ischemia-reperfusion injury

tetracaine

Index Admission and Thirty-day Readmission Outcomes of Cancer Patients Presenting With Stemi

Mohammed Osman - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Dose-Related Reductions in Blood Pressure With a RNA Interference (RNAi) Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results From a First-In-Human Phase 1 Study of ALN-AGT01

Stephen A Huang - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Light Therapy Improves Circadian Blood Pressure Control and Glucose Homeostasis in Rotating Night Shift Workers via Mechanisms Independent of Melatonin

Juliane Hannemann - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arterial stiffness

Melatonin

Copyright © 2026. QuantiNova All rights reserved